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Background The spinal administration of some N-methyl-D- 
aspartate receptor antagonists results in antinociception and 
potentiates the effects of opioids and a,-adrenoceptor agonists, 
but ketamine and its enantiomers have not been examined. The 
present study investigated the interactions of racemic ket- 
amine, R(-)-ketamine and S(+)-ketamine with morphine and 
with dexmedetomidine. 
Methods: lntrathecal catheters were implanted into male 
Wistar rats. Three days later, the acute nociceptive sensitivity 
was assessed using the tail-flick test. Analgesic latencies were 
converted to the percentage maximum possible effect. The dose 
that yielded 50% of the maximum possible effect (ED,,J and 
dose-response and time-course curves were determined for 
the ketamines (30300 pg), morphine (0.1-3.0 pg), dexmedeto- 
midine (0.3-10.0 pg), and mixtures of two doses of ketamines 
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(30 or 100 pg) with different doses of morphine or dexmedeto- 
midine for fixed-dose analysis. 
Results: Neither racemic ketamine nor its enantiomers alone 
had a significant effect on the tail-flick test, with the exception 
of the highest dose of racemic ketamine, which caused motor 
impairment. Morphine and dexmedetomidine each produced 
dose-dependent antinociception, with ED,, of 1.7 pg (95O/o con- 
fidence interval: 1.04-2.32) and 4.85 pg (3.96-5.79), respec- 
tively. A low dose (30 pg) of racemic ketamine or its enanti- 
omers did not influence the ED,, of morphine significantly. 
Coadministration of 100 pg racemic ketamine or S(+)-ket- 
amine, but not R(-)-ketamine, significantly enhanced and pro- 
longed the antinociceptive effect of morphine. Both doses of 
racemic ketamine or its isomers significantly decreased the 
ED5, value for dexmedetomidine, although the higher dose of 
racemic or S(+)-ketamine had the highest potency. One-hun- 
dred micrograms of racemic ketamine or S(+)-ketamine also 
prolonged the effects of dexmedetomidine. 
Conclusions: These data indicate that racemic ketamine and 
S(+)-ketamine, but not R(-)-ketamine, exhibit similar effective- 
ness in potentiating the antinociceptive effects of both mor- 
phine and dexmedetomidine. (Key words: Adrenoceptor; 
NMDA antagonist; opioid; pain; spinal) 
NUMEROUS studies performed at the level of the spinal 
cord have shown that N-methyla-aspartate (NMDA) re- 
ceptor activation plays a role in the transmission of 
nociceptive information. '-* NMDA receptor activation 
does not depolarize dorsal horn neurons in the resting 
state but prolongs action potentials if excitatory im- 
pulses have been initiated by neurokinins or non-NMDA 
excitatory amino acids.' Consequently, blockade of the 
NMDA receptor produces only weak or no antinocicep- 
tion against acute thermal or mechanical stimuli in un- 
injured rats',' but elicits antinociception in various mod- 
els of persistent pain.*x3 
The dissociative anesthetic agent ketamine is a non- 
competitive blocker of glutamate NMDA receptors; it 
exhibits analgesic properties in rodents and humans and 
exerts a direct antinociceptive effect at the spinal lev- 
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The molecular structure of ketamine includes a 
chiral center at C-2 of the cyclohexanone ring, and 
hence two enantiomers of ketamine exist: S( +)-ket- 
amine and R( -)-ketamine. The commercially available 
racemic ketamine preparations contain equal concentra- 
tions of the two enantiomers. The S(+)  enantiomer is 
the more potent at the NMDA receptor.' There have 
been only a few published reports on the analgesic 
properties of the individual optical isomers of ket- 
amine.4.6,s - 10 We have found previously that the behav- 
ioral hyperalgesia associated with carrageenan-induced 
hind paw inflammation in rats is attenuated by the intra- 
thecal administration of racemic ketamine and S( +)- 
ketamine, but not R( -)-ketamine. Neither S( +)-ket- 
amine nor R( -)-ketamine, however, had a significant 
effect on results of the acute heat-pain test." 
Various drugs have been employed clinically for their 
spinal analgesic effects. Opioids administered through 
the intrathecal or epidural route are used widely to treat 
chronic, postoperative, and labor pain. The limitations of 
spinal opioids, however, are considerable. These include 
a variety of side-effects, such as pruritus, nausea, urinary 
retention, hypotension, and respiratory depression.' ' a2- 
Adrenoceptor-mediated spinal analgesia has been inves- 
tigated extensively in animal and human studies. l2 
Dexmedetomidine, the active stereoisomer of medeto- 
midine, is a new, highly selective and potent &,-adreno- 
ceptor agonist. It recently was shown that its intrathecal 
administration causes an antinociceptive effect in ani- 
mals, although it does have some undesired side-effects 
(sedation, diuresis, and mydriasis). 13-" 
An important technique employed to decrease side- 
effects in pharmacology is the use of combinations of 
low doses of several agents that produce the same ther- 
apeutic effects. There are some reports on the interac- 
tions of NMDA antagonists with o p i o i d ~ ' ~ ' ~ - ~ ~  or with 
the classic a2-adrenoceptor agonist clonidine at the spi- 
nal l e ~ e l . ~ ~ , ~ *  No data are available, however, on the 
interactions involved in coadministration of intrathecal 
ketamine and dexmedetomidine, and few articles have 
been published on how the interactions of ketamine and 
morphine after intrathecal or epidural administration 
affect their analgesic proper tie^.'^,^^,^^ To the best of 
our knowledge, no studies have been carried out on the 
interactions of opiates or a,-adrenoceptor agonists with 
the optical isomers S( +)-ketamine and R( -)-ketamine. 
The purpose of the current study was to investigate the 
antinociceptive effects of intrathecal racemic ketamine, 
R( -)-ketamine, and S( +)-ketamine with low doses of 
morphine or dexmedetomidine on acute pain sensa- 
tions, using the tail-flick test in awake rats. 
Methods and Materials 
Intrutbecul Catheterization 
After institutional approval had been obtained from 
our animal care committee, 295 male Wistar rats weigh- 
ing 250 -350 g were studied. For spinal drug administra- 
tion, rats were prepared surgically under anesthesia with 
ketamine and xylazine (87 and 13 mg/kg, respectively, 
intraperitoneally). Because there is a possibility that 
prior exposure to drugs in the same class as those being 
studied (in this case, the same drug being studied- 
ketamine-and the other aZadrenoceptor agonist, xyla- 
zine) may be a confounding variable, we performed 
some sample studies (n = 4 or 5 per group) after barbi- 
turate anesthesia (methohexital sodium, 40 mg/kg intra- 
peritoneally). 
An intrathecal catheter (PE-10 tubing) was inserted 
through a small opening in the cisterna magna and 
passed 8.5 cm caudally into the intrathecal space, as 
previously described.25 After surgery, the rats were 
housed individually, had free access to food and water, 
and were allowed to recover for at least 3 days before 
use. Rats exhibiting postoperative neurologic deficits 
were not used. All experiments were performed during 
the same period of the day (8 :OO A.M. to 1:00 P.M.) to 
exclude diurnal variations in pharmacologic effects. The 
animals were assigned randomly to treatment groups 
(n = 5-13 per group), and the observer was blind to the 
treatment administered. Each animal was studied two or 
three times in an experimental series, with 6 to 8day 
intervals between studies. After experimental use, each 
rat was killed with an overdose of pentobarbital, and 1% 
methylene blue was injected to confirm the position of 
the catheter and the probable spread of the injectate. 
Drugs 
The drugs employed were ketamine hydrochloride 
(Ketalar; Parke-Davis, Vienna, Austria), xylazine hydro- 
chloride (Rompun; Bayer, Leverkusen, Germany), race- 
mic ketamine hydrochloride, R( -)-ketamine hydrochlo- 
ride, S( +)-ketamine hydrochloride (all ketamines for 
intrathecal administration were manufactured by Parke- 
Davis and were generous gifts from Godecke, Vienna, 
Austria), morphine hydrochloride (Alkaloida, Tiszavas- 
vari, Hungary), methohexital sodium (Brietal; Lilly, 
Budapest, Hungary), and dexmedetomidine (a generous 
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gift from Orion-Farmos, Finland). Drugs were dissolved 
in sterile, physiologic saline. The intrathecally adminis- 
tered drugs were injected over 30 s in a volume of 5 pl, 
followed by a 10-pl flush of physiologic saline. 
Nociceptive Testing 
Acute nociceptive sensitivity was assessed using the 
tail-flick test. The reaction time in the tail-flick test was 
determined by immersing the lower 5 cm portion of the 
tail in hot water until a tail-withdrawal response was 
observed (51.5"C water, cut-off time: 20 s). Baseline 
latencies were obtained immediately before and 10, 30, 
60, and 90 min after the drug injections. 
Experimental Paradigm 
Dose-Response Curves for Single Drugs. The first 
series of experiments was performed to determine the 
dose-response and time course for intrathecally admin- 
istered morphine, dexmedetomidine , racemic ketamine , 
R(-)-ketamine, and S(+)-ketamine alone. On the basis 
of preliminary studies, four dosages each of morphine 
(0.1, 0.3 ,  1, and 3 pg) and dexmedetomidine (0 .3 ,  1, 3,  
and 10 pg) and three dosages each of racemic ketamine 
and its enantiomers (30, 100 and 300 pg) were examined. 
Drug Interactions. The second series of experiments 
was performed with a fixed dose of S(+)-ketamine, 
R(-)-ketamine, or racemic ketamine (30 or 100 pg), 
with different doses of morphine (0.03-3.0 pg) or 
dexmedetomidine (0.1-3.0 pg), in order to determine 
the effects of racemic ketamine and its enantiomers on 
morphine- or dexmedetomidine-induced antinocicep- 
tion after ketamine-xylazine anesthesia. 
Experiments after Methohexital Anesthesia. Stud- 
ies with two dose levels of morphine (0.3 and 1 pg) and 
dexmedetomidine (0 .3  and 3 pg) alone were performed. 
We also investigated the effects of 100 pg racemic ket- 
amine or S(+)-ketamine on the morphine- or dexme- 
detomidine-induced antinociception. 
Statistical Analysis 
Analgesic latencies in acute pain tests were converted 
to the percentage maximum possible effect using the 
formula: 
Percentage maximum possible effect = 
([observed latency - baseline latency]/ 
[cutoff - baseline latency]) X 100 
Data are presented as the mean -+ SEM. Because all 
drugs and their combinations generally resulted in in- 
creases in the thermal withdrawal latency, with the peak 
effect occurring within 10 -30 min, the values obtained 
at 10 and 30 min were averaged in order to obtain the 
value for each dosage. Dose-effect curves were con- 
structed for each drug or drug combinations. The dos- 
ages that yielded 50% of the maximum possible effect 
(ED50) and the 95% confidence intervals were calculated 
by linear regression. Data sets were examined by one- 
and two-way analyses of variance. Individual group 
means were compared by using the Student t test. P < 
0.05 was considered significant. 
Results 
There was no significant difference in tail-flick latency 
between the groups (7.0 2 0.10 s) before drug admin- 
istration. The tail-flick latencies of the control group did 
not change significantly during the period of the inves- 
tigation. 
Single Drug Studies 
Morphine and dexmedetomidine, but not racemic ket- 
amine and its enantiomers, resulted in dose-dependent 
increases in the thermal withdrawal latency, with the 
peak effect of either drug occurring within 30 min (fig. 
1 ) .  The rank order of potencies, with ED& was mor- 
phine 1.7 pg (95% confidence interval: 1.04 -2.32) fol- 
lowed by dexmedetomidine 4.85 pg (3.96-5.79).  The 
intrathecal injection of morphine in the dose range 
tested did not interfere with the gross behavior of the 
animals. Dexmedetomidine at higher doses ( 3  and 10 
pg) was associated with substantial diuresis and sedation 
(decreased spontaneous exploring activity, but still re- 
sponsive to acoustic or tactile stimuli). Racemic ket- 
amine and S(+)-ketamine in the highest dose (300 pg), 
but not the R ( - )  enantiomer, caused a short-lasting 
motor impairment. In the combination experiments, 
therefore, we applied only 30 or 100 pg racemic ket- 
amine, or its enantiomers, which did not cause any side 
effects. 
Double-combination Studies 
In the special case of an agent lacking effectiveness, 
any statistically significant decrease in the ED,, of the 
other, active component denotes potentiation or syner- 
gism. As such, the larger dose (100 pg) of intrathecal 
S( +)-ketamine and racemic ketamine, but not R( -)-ket- 
amine, synergistically enhanced the antinociception 
from intrathecal morphine, reducing its ED5, (table). 
The decrease in ED,, after the lower dose of racemic 
ketamine or its enantiomers was not significant, and the 
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Fig. 1. Time courses of the antinociceptive effects (percentage 
maximum possible effect) of intrathecdy administered race- 
mic ketamine, s(+)-ketamine, and R(-)-ketamine. Each point 
represents the mean f SEM of the data from 5-14 animals. *P < 
0.05 versus baseline; +P < 0.05 versus saline. 
linear regression curves shifted to the left after either 
racemic ketamine or S( +)-ketamine (100 pg) coadmin- 
istration with morphine, but not after R( -)-ketamine 
All of the ketamine treatments significantly reduced 
the ED5, value of dexmedetomidine (table), although 
100 pg S(+)-ketamine and racemic ketamine were the 
(fig. 2). 
Table 1. ED5, (pg) with 95% Confidence Interval (CI) for 
DOSe-eSDOnSe Curve of Intrathecal Agents 
Auents ED, 95% CI 
Morphine 1.66 1.04-2.32 
30 pg S(+)-ketarnine + morphine 1.19 0.55-1.81 
100 pg S(+)-ketamine + morphine 0.16* 0.01-0.39 
30 pg Racemic-ketamine + morphine 1.04 0.64-1.44 
100 pg Racemic-ketarnine + morphine 0.1V 0.02-0.71 
30 pg R(-)-ketamine + morphine 2.61 0.24-3.55 
100 pg R(-)-ketarnine + morphine 2.32 0.55-3.35 
Dexmedetomidine 4.85 3.96-5.79 
30 pg S(+)-ketamine + dexrnedetomidine 1.3T 0.94-1.83 
100 pg S(+)-ketamine + dexmedetomidine 0.15* 0.01-1.54 
30 pg Racemic-ketamine + dexmedetomidine 2.15* 1.29-2.92 
100 pg Racernic-ketarnine + dexrnedetomidine 0.18* 0.01-1.88 
100 pg R(-)-ketamine + dexmedetomidine 1.39* 0.5-2.33 
’ Significant difference from the result of morphine or dexmedetomidine 
alone. 
30 pg R(-)-ketamine + dexmedetomidine 1.83* 0.99-2.72 
most effective in this potentiation. The linear regression 
curves shifted to the left after either racemic ketamine or 
coadministration of both enantiomers (30 or 100 pg) 
(fig. 2).  
The time-course curves (figs. 3 and 4) revealed that 
smaller doses of racemic ketamine or its enantiomers did 
not influence the antinociceptive effects of morphine at 
any time point, although they potentiated the antinoci- 
ceptive effects of dexmedetomidine. Racemic or S( +)- 
ketamine in the higher dose (100 pg), however, not only 
potentiated but also prolonged the antinociceptive ef- 
fect of either morphine or dexmedetomidine. Moreover, 
S(+)-ketamine (100 pg) with 0.3 pg morphine or 
dexmedetomidine caused a longer antinociception than 
the racemic ketamine combinations (figs. 3 and 4). In no 
other cases were any differences observed between ra- 
cemic ketamine and S(+)-ketamine (100 pg). Animals 
receiving the combinations exhibited no severe side- 
effects or unusual behavior. 
Results after Methohexital Anesthesia 
The analysis of the time-course curves after methohexi- 
tal anesthesia revealed that, similar to ketamine-xylazine 
anesthesia, morphine and dexmedetomidine cause dose- 
dependent antinociception, and both racemic ketamine 
and S(+)-ketamine potentiated this effect (fig. 5). 
Discussion 
This is the first study of the antinociceptive properties 
of coapplied ketamine and dexmedetomidine and ket- 
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Fig. 2. Log dose-response curves for the antinociceptive effects (percentage maximum possible effect) of intrathecally administered 
morphine (Zefi) or dexmedetomidine (right), alone or with the addition of 30 or 100 pg racemic ketamine, R(-)-ketamine, or 
S(+)-ketamine. Each point represents the mean k SEM of the data from 5-14 animals. 
amine and morphine in which the effectiveness of S(+)- 
ketamine, R( -)-ketamine, and racernic ketamine admin- 
istered intrathecally to rats were compared using an 
acute heat-pain test. We observed synergistic interac- 
tions between the higher dose of racemic ketamine or 
S(+)-ketamine and morphine or dexmedetomidine, and 
this potentiation was independent of the anesthetic drug 
applied. Coadministration of a low dose of morphine or 
dexmedetomidine (0.3 pg) with S(+)-ketamine (100 
Fg), which in itself induced no changes in pain sensation 
or behavior, caused a significant long-lasting antincoci- 
ception, without any side-effects. Ketamine was more 
effective after coadministration with dexmedetomidine, 
and this potentiation could be observed after R(-)-ket- 
amine coadministration as well. 
The dissociative anesthetic agent ketamine is a non- 
competitive blocker of glutamate NMDA receptors, act- 
ing on the phencyclidine site; it exhibits analgesic prop- 
erties in rodents and humans.4x599 It binds to opioid and 
acetylcholine receptors also, but the affinity of ketamine 
for these receptors is lower than that for the NMDA 
channel, which suggests that the interaction is not of 
major clinical importance.428 The intrathecal administra- 
tion of ketamine produces only weak or no analgesic 
effects against acute pain, such as that in the tail-flick 
test,' although ketamine reduces the hyperalgesic effect 
of a hind paw carragenan injection2" and of nerve inju- 
Various studies already have demonstrated the benefi- 
cial antinociceptive effect of opioids and NMDA recep- 
tor antagonists coadministrated by either a systemic28229 
or an intrathecal route. 18820,30-33 Powerful synergism 
arises from combinations of threshold doses of mor- 
phine with low doses of NMDA  antagonist^,^'-^^ in 
ever, failed to observe any potentiation of NMDA recep- 
ry.26,27 
agreement with our results. Other studies, 18-20 how- 
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Fig. 3. Time course of antinociceptive ef- 
fects (percentage maximum possible ef- 
fect) for various mixtures of 30 or 100 pg 
u racemic ketamine, R(-)-ketamine, or 
L S(+)-ketamine with morphine. Each 
s point represents the mean f SEM of the 
data from 5-14 animals. *P < 0.05 versus 
baseline; +P < 0.05 versus sahe; xP < 
0.05 versus racemic ketamin+morphine 
100 
0 
-50 
o 25  so 7 5  100 treatment. 
Time( min) 
1 pg morphine + 
100 pg ketamine 
0 is 
tor antagonists on morphine-induced antinociception in 
acute pain tests. This discrepancy may be a result of the 
different methods of drug administration or differences 
in the applied dose or the applied pain tests. 
Many previous studies have indicated that the intrathe- 
cal administration of a,-adrenoceptor agonists produces 
analgesia in animals and humans. 12-14,34,35 Intrathecal 
a,-adrenergic agonists mimic the effects of endogenous 
norepinephrine and may produce antinociception by 
decreasing the release of glutamate from primary affer- 
ent nerve  terminal^,^^ thereby suppressing the activity of 
wide dynamic range neurons evoked by noxious stimu- 
i o  i s  100 
Time(min) 
li.37 The systemic coadministration of an a2-adrenocep- 
tor agonist (ie., clonidine, xylazine, or medetomidine) 
and an NMDA antagonist (especially ketamine) in animal 
studies provides adequate analgesia, muscle relaxation, 
and complete immobilization; this is therefore a widely 
used combination in veterinary ane~thesia.~' Behavioral 
and electrophysiologic studies in rodents indicated the 
importance of adrenoceptors in modulating the behavior 
and excitation induced by the intrathecal administration 
of NMDA.39,40 Only a few data are available on the 
interactions between these drugs after intrathecal ad- 
ministration; for example, Lee and Yaksh2* have shown 
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Fig. 4. Time course of antinociceptive ef- 
fects (percentage maximum possible ef- 
fect) for various mixtures of 30 or 100 pg 
racemic ketamine, R(-)-ketamine, or 
S(+)-ketamine with dexmedetomidine. 
Each point represents the mean 2 SEM of 
the data from 5-14 animals. *P < 0.05 
versus baseline; +P < 0.05 versus saline; 
xp < 0.05 versus racemic ketamine- 
dexmedetomidine treatment. 
0.3 dexmedetomidine + 
30 pg ketamine 0.3 pg dexrnedetomidine + 
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-o- S(+)-ketamtne 100 
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52 z 
0 
0 25 50 75 100 
Time( min) 
I pg dexmedetomidine + 
30 pg ketamine 
0 25 50 75 100 
Time( min) 
3 pg dexrnedetornidine + 
30 vg ketarnine 
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52 z 
0 
-50 
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that the intrathecal coadministration of clonidine and 
MK-801 results in a dose-dependent increase in the me- 
chanical pain threshold in a peripheral neuropathic pain 
rat model. 
There are several possibilities for synergistic interac- 
tion between ketamine and morphine or dexmedetomi- 
dine. Because opioid, glutamate, and a,-adrenergic re- 
ceptors are abundant in the spinal cord,*’ coactivation 
and antagonisms of these receptors could have a bene- 
ficial effect on the inhibition of pain sensation at low 
dosages, which cause minimal side-effects. There are 
differences in mechanism of action between ketamine 
1 L 
-50 
0 25 SO 75 100 
Time( min) 
1 pg dexmedetomidine + 
100 pg ketarnine 
‘OOl 
-50-oo 0 
Time( min) 
3 pg dexmedetomidine + 
100 pg ketarnine 
’+ w 50 52 
z 
0 
-50-00 0 
Time( min) 
and morphine or dexmedetomidine. Ketamine decreases 
the activation of dorsal horn neurons, by inhibiting the 
ionotropic glutamate receptor opening.’ A major mech- 
anism of spinal opioid and a,-adrenoceptor agonist an- 
algesia is the inhibition of transmitter release from the 
C-fiber primary afferent terminal, although they have 
inhibitory effects on both interneurons and projecting 
 neuron^.^",*^-^* Presynaptic action of these drugs con- 
tram with the postsynaptic location of the NMDA re- 
ceptor. The dual actions at both pre- and postsynaptic 
sites allow the possibility of synergy. It is also possible 
that the augmented activity results from a decreased 
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clearance of drugs from the intrathecal space, because 
the duration of action of the combinations was longer 
than that of morphine or dexmedetomidine alone. 
The potential advantages of using a pure enantiomer 
rather than a racemate include a less complex and more 
selective pharmacodynamic profile, a higher therapeutic 
index, and less complex pharmacokinetics, drug inter- 
actions, and concentration-response relations. For finan- 
cial reasons, pure isomers so far have been used only for 
research purposes, but the wide-ranging clinical use of 
pure isomers now is financially feasible, because of new 
production  technique^.^^ Marietta et al. lo reported dif- 
ferences in the pharmacologic potencies of the optical 
isomers of ketamine in rats. Human studies revealed 
differences in anesthetic potency, intraoperative effects, 
postoperative analgesia, and side-effects of the two en- 
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antiorner~.~' The S(+)  enantiomer has four times the 
potency of the R ( - )  enantiomer of ketamine as an an- 
esthetic, and it may have significant clinical advantages 
in comparison with the racemic drug, such as fewer 
side-effects. Differences also exist in the pharmacokinet- 
ics of the ketamine enantiomers. If they are administered 
individually, the plasma clearance of S( +)-ketamine is 
greater than that of the R ( - )  enantiomer. Kharasch and 
Labr~o*~ have demonstrated a relative enantiomeric se- 
lectivity in the human metabolism. Not all of the effects 
of ketamine, however, are stereo~elective.~~~" We previ- 
ously examined the effects of the two isomers of ket- 
amine on acute and inflammatory pain sensations in 
rats.' We found that the behavioral hyperalgesia associ- 
ated with carrageenan-induced hind paw inflammation 
in rats is attenuated by the intrathecal administration of 
racemic ketamine or S( +)-ketamine, but not R( -)-ket- 
amine; neither S( +)-ketamine nor R( -)-ketamine had a 
significant effect on results of the tail-flick test. 
Racemic ketamine has been administered epidurally to 
humans for pain relief without side-effects such as respi- 
ratory depression, urinary retention, or pruritus that fre- 
quently are observed after epidural o p i o i d ~ . ~ ~  The 
neuraxial use of NMDA receptor antagonists has raised 
the question of potential although neuro- 
logic lesions have not been reported after intrathecal 
administration of racemic ketamine in human studies.49 
In a study by Kristensen et aZ.,51 the chronic intrathecal 
administration of pharmacologically active doses of dif- 
ferent NMDA receptor antagonists in rats did not pro- 
duce neurotoxic effects in the spinal cord. There is now 
a clinical report, however, of neurotoxiciy from intrathe- 
cal ketamine with benzathonium chloride as a preserva- 
t i ~ e . ~ ~  Preservatives (benzathonium chloride or chloro- 
butanol) used in ketamine solution in some cases were 
thought to cause neurologic damage in animals. The 
isomers of ketamine do not themselves induce spinal 
cord lesions, but the preservative chlorobutanol leads to 
significant spinal cord damage in rabbits,5o and benze- 
thonium chloride is toxic in swine,53 but not in pri- 
m a t e ~ . ~ *  In one study that used preservative-free ket- 
amine, vacuolation of the dorsal root ganglia occurred in 
three rats that suddenly died (500 ~ g ) . ~  
The fact that S( +)-ketamine had a higher efficacy than 
racemic ketamine agrees only with some earlier re- 
s u l t ~ . ' , ~ ~  There might be several explanations for this. 
Pharmacokinetically, we presume that in the racemic 
combination, R(-)-ketamine decreases the elimination 
of S(+)-ketamine, as suggested by Kharasch and La- 
br00.~' Further, it has been shown that R(-)-ketamine 
also binds to the NMDA receptors, but with lower affin- 
ity,7 and our previous results suggested that R( -)-ket- 
amine has a tendency to cause significant antinocicep- 
tion.' The fact that both enantiomers of ketamine 
potentiated the antinociceptive effects of dexmedetomi- 
dine is in line with these results. 
One approach to improve analgesia is to combine 
small doses of analgesics that interact synergistically to 
produce analgesia without increasing the side-effects. 
There is a risk of delayed hallucinations from intrathecal 
racemic ketamine, as Kristensen et aL5' described for 
another NMDA receptor antagonist administered intra- 
thecally to humans, but there were no previous human 
data on the intrathecal administration of S( +)-ketamine. 
The subjective mood was judged to be significantly bet- 
ter, and no unpleasant dreams were reported after sys- 
temic S( +)-ketamine compared with the group treated 
with racemic ketami~~e.*~ Although these side effects 
cannot be predicted from rat studies, we did observe 
motor impairment at the highest dose (300 pg). Simi- 
larly, side-effects also were observed often in response to 
high doses of morphine and dexmedetomidine alone, 
but not in combination with ketamine, at much lower 
doses. Finally, because the commercially available S( +)- 
ketamine preparation does not contain preservatives, 
and toxicologic assessments have demonstrated that it is 
innocuous in two animal it appears that it 
may be appropriate to administer S( +)-ketamine intra- 
thecally to humans in small doses. 
The intrathecal administration of racemic ketamine 
and S( +)-ketamine alone caused no antinociception to a 
thermal stimulus in rats, but significantly potentiated and 
prolonged morphine or dexmedetomidine-induced an- 
tinociception. R(-)-ketamine potentiated the antinoci- 
ceptive effect of dexmedetomidine, but not that of mor- 
phine. Our data provide additional evidence concerning 
the notion that the pure enantiomer S(+)-ketamine can 
be a potent component of combined antinociceptive 
therapy. These findings may provide a rationale for com- 
bining such drugs for improved human postoperative 
pain treatment in the future. 
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